Evidence map›Paper›PMID 31748414›Full record

ArticleThe Journal of biological chemistry2020

Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis.

Maria V Liberti, Annamarie E Allen, Vijyendra Ramesh, Ziwei Dai, Katherine R Singleton, Zufeng Guo, Jun O Liu, Kris C Wood, Jason W Locasale

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maria V LibertiDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710; Department of Molecular Biology and Genetics, Cornell University, Ithaca, New York 14853. Electronic address: mliberti@rockefeller.edu.
Annamarie E AllenDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Vijyendra RameshDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Ziwei DaiDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Katherine R SingletonDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Zufeng GuoDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Jun O LiuDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Kris C WoodDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Jason W LocasaleDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710.
Duke University · USJohns Hopkins University · US

Funding

Pharmacological Sciences Training ProgramT32GM007105 · NIGMS · DUKE UNIVERSITY · PI KUHN, CYNTHIA M · 1985 to 2019
$9.0M
Dietary methionine and cancerR01CA193256 · NCI · DUKE UNIVERSITY · PI LOCASALE, JASON W. · 2015 to 2023
$3.1M
Understanding metabolic flux and the control of mammalian cell growthR00CA168997 · NCI · DUKE UNIVERSITY · PI LOCASALE, JASON W. · 2013 to 2015
$695k
Examining Biosynthesis and NAD+ Demand in the Warburg EffectF31CA232658 · NCI · DUKE UNIVERSITY · PI ALLEN, ANNAMARIE ELIZABETH · 2019 to 2021
$111k
Metabolic and Genetic Heterogeneity in CancerF99CA222986 · NCI · CORNELL UNIVERSITY · PI LIBERTI, MARIA V · 2017 to 2018
$83k
NCI NIH HHS F31 CA232658NCI NIH HHS F99 CA222986NCI NIH HHS R00 CA168997NCI NIH HHS R01 CA193256NIGMS NIH HHS T32 GM007105
6 · The paper itself

Abstract

Aerobic glycolysis or the Warburg effect (WE) is characterized by increased glucose uptake and incomplete oxidation to lactate. Although the WE is ubiquitous, its biological role remains controversial, and whether glucose metabolism is functionally different during fully oxidative glycolysis or during the WE is unknown. To investigate this question, here we evolved resistance to koningic acid (KA), a natural product that specifically inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a rate-controlling glycolytic enzyme, during the WE. We found that KA-resistant cells lose the WE but continue to conduct glycolysis and surprisingly remain dependent on glucose as a carbon source and also on central carbon metabolism. Consequently, this altered state of glycolysis led to differential metabolic activity and requirements, including emergent activities in and dependences on fatty acid metabolism. These findings reveal that aerobic glycolysis is a process functionally distinct from conventional glucose metabolism and leads to distinct metabolic requirements and biological functions.

Indexed as

GlycolysisEnzyme InhibitorsFatty AcidsGlucoseGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)HumansMCF-7 CellsOxygenSesquiterpenesEnzyme InhibitorsFatty AcidsGAPDH protein, humanGlucoseGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)heptelidic acidOxygenSesquiterpenescancerglucose metabolismglyceraldehyde-3-phosphate dehydrogenase GAPDHglycolysismass spectrometry (MS)metabolic regulationmetabolic reprogrammingmetabolomicsoxidative metabolismWarburg effect

Identifiers

PMID31748414
PMCPMC6952593
OpenAlexW2991453804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.